Job title: Principal Scientist, Analytical Development - Gene therapy & Biologics
Dr. Marina Feschenko is currently a Principal Scientist at Biogen. She has been with the company for 8.5 years. Marina is a group leader in Bioassay development for gene therapy and biologics drug candidates. She previously worked for Pfizer and Adolor Corporation. Marina holds Ph.D. from Shemyakin Institute of Bioorganic Chemistry in Russia where her work was focused on monoclonal antibody generation and characterization. Dr. Feschenko underwent postdoctoral training in cell biology and signaling at MGH and Harvard Medical School.
Potency Assessment for Novel AAV-Based Drugs: Exploration of Different Biological Activities & Stability Indicating Properties of the Assays 1:15 pm
There are three major types of in-vitro analytical assays for assessment of biological activity of AAV-based therapeutics: infectivity, target protein expression, and functional potency It is important to understand what information each assay can provide and how it can be used for process development and drug characterization Changes in AAV vector structure affect three biological…Read more
day: Day One